Skip to Content
Merck
CN
  • Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.

Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.

Genome biology (2011-12-22)
Olivier Harismendy, Richard B Schwab, Lei Bao, Jeff Olson, Sophie Rozenzhak, Steve K Kotsopoulos, Stephanie Pond, Brian Crain, Mark S Chee, Karen Messer, Darren R Link, Kelly A Frazer
ABSTRACT

Ultra-deep targeted sequencing (UDT-Seq) can identify subclonal somatic mutations in tumor samples. Early assays' limited breadth and depth restrict their clinical utility. Here, we target 71 kb of mutational hotspots in 42 cancer genes. We present novel methods enhancing both laboratory workflow and mutation detection. We evaluate UDT-Seq true sensitivity and specificity (> 94% and > 99%, respectively) for low prevalence mutations in a mixing experiment and demonstrate its utility using six tumor samples. With an improved performance when run on the Illumina Miseq, the UDT-Seq assay is well suited for clinical applications to guide therapy and study clonal selection in heterogeneous samples.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Trizma® hydrochloride solution, pH 8.0, BioPerformance Certified, 1 M, suitable for cell culture